Serum level of fibronectin in patients with arterial hypertension

  • L. A. Mogylnytska Khmelnytsky regional hospital
  • B. N. Mankovsky Shupik’s National Medical Academy of Postgraduate Education
Keywords: fibronectin, arterial hypertension, endothelium-dependent dilatation, endothelial dysfunction

Abstract

To investigate serum levels of fibronectin in hypertensive patients, as a marker of endothelial dysfunction, the relationship of this factor of endothelium-dependent dilatation and other risk factors of cardiovascular disease. Were examined 68 hypertensive patient and 18 control subjects. Serum levels of fibronectin were determined by immunoenzyme assay. Endothelium-dependent dilatation was measured by standard method of Celermajer. Were found an increased serum level of fibronectin in hypertensive patients compared to control (336,48 pmol/ml ± 71,73 pmol/ml and 222,66 pmol/ml ± 36,93 pmol/ml respectively; Р < 0,05). Also, the level of fibronectin correlated with endothelium-dependent dilatation, serum levels of insulin, HOMA, total cholesterol, HDL, LDL, triglycerides, HbA1c, blood glucose, body mass index (Р < 0,05). There is an elevation of serum level of fibronectin and an alteration of endothelium-dependent dilatation in arterial hypertension. Hyperglycemia, dyslipidemia, insulin resistance, and obesity appears to be significant factor to contributing elevation of fibronectin. The revealed change could reflect an endothelial dysfunction in this pathological state.

Downloads

Download data is not yet available.

References

1. Могильницька Л. А. Вміст фібронектину у сироватці крові хворих на цукровий діабет 2-го типу та ожиріння // Клін. ендокринологія та ендокринна хірургія. – 2012. – Вип. 41, № 4. – С. 44–48.

2. Могильницкая Л. А. Содержание фибронектина в сыворотке крови больных сахарным диабетом 1-го типа с микроангиопатиями, болеющих с детства и у лиц с ожирением // Пробл. эндокринологии. – 2015. – Т. 61, № 1. – С. 36–40.

3. Adegbija O., Hoy W. E., Wang Z. Waist circumference values equivalent to body mass index points for predicting absolutecardiovascular disease risks among adults in an Aboriginal community: a prospective cohort study // BMJ Open. – 2015. – Vol. 5, N 11. – P. 0091–0085.

4. Barton M., Baretella O., Meyer M. R. Obesity and risk of vascular disease: importance of endothelium-dependent vasoconstriction // Br. J. Pharmacol. – 2012. – Vol. 165, N 3. – P. 591–602.

5. Bauters C., Marotte F., Hamon M. et al. Accumulation of fetal fibronectin mRNAs after balloon denudation of rabbit arteries // Circulation. – 2005. – Vol. 92. – P. 904–911.

6. Bornfeldt K. E., Tabas I. Insulin resistance, hyperglycemia, and atherosclerosis // Cell. Metab. – 2011. – Vol. 14, N 5. – P. 575–585.

7. Celermajer D. S., Sorensen K. E., Gooch V. M. et al. Non-invasive detection of endothelial dysfunction in children and adults at risk for atherosclerosis // Lancet. – 1992. – Vol. 340. – P. 1111–1115.

8. ESH/ESC Task Force for the Management of Arterial Hypertension. 2013 Practice guidelines for the management of arterial hypertension of the European Society of Hypertension (ESH) and the European Society of Cardiology (ESC): ESH/ESC Task Force for the Management of Arterial Hypertension // J. Hypertens. – 2013. – Vol. 31, N 10. – P. 1925–1938.

9. Goff D. C. Jr., Lloyd-Jones D. M., Bennett G. et al. American College of Cardiology / American Heart Association Task Force on Practice Guidelines. 2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines // J. Am. Coll. Cardiol. – 2014. – Vol. 63. – P. 2935–2959.

10. Grossman E., Messerli F. H. Hypertension and diabetes // Adv. Cardiol. – 2008. – Vol. 45. – P. 82–106.

11. Hynes R. O. Fibronectins // Sci. Am. – 2006. –Vol. 254. – p. 42–51.

12. Kaźmierski M., Michalewska-Włudarczyk A., Krzych L. J., Tendera M. Diagnostic value of flow mediated dilatation measurement for coronary artery lesions in men under 45 years of age // Cardiol. J. – 2010. – Vol. 17, N 3. – P. 288–292.

13. Martín-Timón I., Sevillano-Collantes C., Segura-Galindo A., Del Cañizo-Gómez F. J. Type 2 diabetes and cardiovascular disease: Have all risk factors the same strength?// World J. Diabetes. – 2014. – Vol. 5, N 4. – P. 444–470.

14. Matthews D. R., Hosker J. P., Rudenski A. S.et al. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man // Diabetologia. – 1985. – Vol. 28. – P. 412–419.

15. Mauricio M. D., Aldasoro M., Ortega J., Vila J. M. Endothelial dysfunction in morbid obesity // Curr. Pharm. Des. – 2013. – Vol. 19. – P. 5718–5729.

16. Reriani M. K., Lerman L. O., Lerman A. Endothelial function as a functional expression of cardiovascular risk factors // Biomark. Med. – 2010. – Vol. 4. – P. 351–360.

17. Rubinshtein R., Kuvin J. T., Soffler M. et al. Assessment of endothelial function by non-invasive peripheral arterial tonometry predicts late cardiovascular adverse events // Eur. Heart. J. – 2010. – Vol. 31. – P. 1142–1148.

Abstract views: 28
PDF Downloads: 14
Published
2017-03-30
How to Cite
Mogylnytska, L. A., & Mankovsky, B. N. (2017). Serum level of fibronectin in patients with arterial hypertension. Likars’ka Sprava, (1-2), 60-65. Retrieved from https://liksprava.com/index.php/journal/article/view/10
Section
Original intestigations